Note: this report is based exclusively on primary sources such as Pharming’s own press releases, corporate presentations and SEC/Nasdaq filings, plus official regulatory designations for the pipeline assets. No secondary blogs or non-verifiable commentary were used for the factual data.

1. What exactly happened: FDA CRL for pediatric Joenja (APDS 4–11 years)

On February 1, 2026, Pharming announced that the U.S. FDA issued a Complete Response Letter (CRL) to its supplemental New Drug Application (sNDA) for Joenja (leniolisib) in children aged 4 to 11 years with activated phosphoinositide 3-kinase delta syndrome (APDS). The letter does not question the fundamental clinical benefit of leniolisib in APDS but raises two specific technical concerns:

First, the FDA wants additional pharmacokinetic (PK) data to confirm that children in the lower weight dose groups can reliably achieve exposure levels comparable to the already approved adolescent/adult regimen. In other words, the Agency is not fully convinced that the dose-exposure relationship in lighter pediatric patients is sufficiently characterized and wants more hard data and modelling around it.

Second, the CRL identifies an issue with one of the analytical methods used for manufacturing batch testing. The Agency is asking for additional data and clarification about that analytical method, which sits in the chemistry, manufacturing and controls (CMC) side of the file.

Importantly, the company emphasizes that there were no new safety signals and that the CRL does not affect the existing Joenja label for patients 12 years and older. The adult/adolescent approval, granted in March 2023 in the U.S. and subsequently in the UK and other territories, remains in force.

The pediatric sNDA had been under Priority Review since October 2025, reflecting FDA’s view that a targeted treatment for younger APDS patients could represent a significant improvement versus current options, which are essentially supportive or transplant-based and not specifically designed for the underlying PI3Kδ-driven immune dysregulation.

2. What a CRL means in practice – and the likely regulatory trajectory

A Complete Response Letter means the FDA has completed the review but cannot approve the application in its current form. It is not the same as a rejection of the drug itself; it is a detailed list of deficiencies that must be resolved before the Agency can consider approval.

In this case, the message is focused on exposure in low-weight children and on the robustness of a specific batch-testing analytical method. The CRL does not call for a brand-new, large scale efficacy trial or question the overall benefit-risk profile that was already demonstrated in the randomized Phase III trial in adolescents and adults, and in the open-label pediatric Phase III study.

Pharming states that it believes it can address both the clinical pharmacology and the methodology issues and plans to request a Type A meeting with FDA to agree on the most efficient package to resubmit the application. That meeting will be critical for investors, because it should clarify:

• whether the Agency is open to additional PK analyses and modelling using existing data and samples, possibly supplemented by a small bridging study, or whether a broader study in low-weight children will be required;
• what exact validation or re-validation steps, comparability exercises and documentation are expected to resolve the analytical-method concern.

Until that meeting happens and the minutes are published by the company, the timeline for resubmission and potential approval is uncertain. If the FDA accepts a focused PK/CMC package built mainly from existing material, resubmission could be relatively fast. If a new dedicated clinical PK trial in low-weight children is required and recruitment is slow, the delay could be more substantial.

3. The Joenja franchise: adult label intact, pediatric expansion delayed

From a commercial standpoint, it is important to distinguish between:

• the current Joenja label, which covers APDS patients 12 years and older in the U.S. and certain other markets;
• the pediatric expansion for 4–11 years, which is exactly what the sNDA and the CRL are about.

The existing label is unaffected by the CRL. Joenja continues to be marketed in the U.S. with increasing patient numbers, and the company is working on geographic expansion and access programs in Europe and other regions. In the 4Q/FY 2024 presentation, Pharming reported:

• total 2024 revenues of around US$297M (+21% vs 2023), with Joenja contributing roughly US$45M (up strongly from 2023) and RUCONEST around US$252M;
• an in-market U.S. Joenja demand that is still ramping, with more than 240 APDS patients identified in the U.S. and more than 880 globally, and 96 patients on paid therapy plus additional patients in access programs and studies;
• 4Q 2024 revenue of ~US$93M and a return to operating profit and positive operating cash flow in the second half of the year.

Joenja pricing remains in the high-orphan range, with a WAC (wholesale acquisition cost) in the U.S. of roughly US$49,500 for a 30-day supply (about US$594,000 per year), which naturally makes each incremental treated patient economically meaningful for the company but also places a premium on payer negotiations and value demonstration.

For the pediatric segment, the company had presented positive topline Phase III data in children 4–11 in December 2024, showing improvements in lymphadenopathy and naïve B-cell counts consistent with what had already been seen in older patients. The CRL, therefore, is not a comment on the absence of effect, but on the strength of the exposure and analytical underpinnings of the file.

4. Financial position and 2025–2026 profile

On the financial side, Pharming enters this CRL moment with a relatively robust base:

• 2024 total revenues of about US$297M, with Joenja and RUCONEST both growing;
• an overall cash and marketable securities position of around US$169M at year-end 2024 (vs. ~US$173M at the end of 3Q 2024), after financing activities and the upfront costs related to the Abliva acquisition;
• positive operating profit and positive operating cash flow in 3Q–4Q 2024, indicating that the base business is able to self-fund most of the ongoing R&D and commercial investments.

For 2025, the company had originally guided to revenues in the US$315–335M range, i.e. 6–13% growth versus 2024. In January 2026, however, Pharming reported preliminary 2025 revenues of approximately US$376M, significantly above that range. This suggests that Joenja and RUCONEST continued to perform well in 2025, before the CRL headline, and that the rare disease portfolio has meaningful momentum.

Management also highlighted that available cash and expected future cash flows should be sufficient to cover the development and pre-launch costs of KL1333 (discussed below) and the expansion programs for leniolisib beyond APDS, including additional PIDs and CVID with immune dysregulation.

5. Pipeline beyond pediatric APDS: PIDs, CVID and KL1333

The CRL does not affect the broader development arc of leniolisib and of Pharming’s new mitochondrial-disease asset KL1333.

5.1. Leniolisib in PIDs with immune dysregulation and in CVID

APDS is just the most clearly defined of a broader cluster of primary immunodeficiencies driven by PI3Kδ pathway hyperactivation. Pharming has been very explicit about working on:

• a Phase II trial in PIDs with immune dysregulation linked to PI3Kδ signaling, covering conditions such as CTLA4 haploinsufficiency, ALPS-FAS, NFKB1 haploinsufficiency and PTEN deficiency, among others;
• a Phase II trial in common variable immunodeficiency (CVID) with immune dysregulation, a larger but clinically similar population where no targeted therapies are available.

In their 4Q/FY 2024 presentation and subsequent updates, Pharming noted that:

• the PIDs-with-immune-dysregulation trial has Fast Track designation from FDA and is ongoing as a single-arm, open-label, dose-finding study;
• the CVID trial started dosing around late March 2025, after positive regulatory feedback on the rationale and unmet need;
• prevalence estimates suggest around 1.5 APDS patients per million, roughly 7.5 per million PIDs linked to PI3Kδ and about 39 per million CVID with immune dysregulation, indicating that successful label expansions could meaningfully enlarge the leniolisib opportunity over time.

5.2. KL1333 for primary mitochondrial disease (Abliva acquisition)

In parallel, Pharming has moved to diversify its pipeline beyond immunology by acquiring Abliva AB, the Swedish company that developed KL1333, an oral small molecule for certain forms of primary mitochondrial disease (PMD).

The deal, announced in December 2024 as a public cash offer to Abliva shareholders, values the transaction at about US$66M and brings in an asset that:

• has Fast Track designation from FDA and Orphan Drug designation in both the U.S. and Europe;
• is being tested in the pivotal Phase II FALCON study, where an interim analysis has already been positive and aligned with the FDA-agreed primary endpoints;
• targets a patient population with virtually no approved therapies and a high burden of fatigue, muscle weakness and reduced life expectancy.

Pharming’s materials indicate that the FALCON read-out is anticipated in 2027, with a potential FDA filing and, if successful, approval around 2028. This is a medium-term catalyst but fits the broader narrative: building a focused rare-disease portfolio where the company can leverage the same infrastructure (specialty field teams, patient finding, reimbursement expertise) across multiple indications.

6. Scenario thinking: how big is the CRL in the grand scheme?

From a trading and investment perspective, the key question is not whether a CRL is “good” or “bad” – any CRL is negative versus a clean approval – but how deep and long-lasting the impact is likely to be relative to Pharming’s overall trajectory.

A concise way to frame it is in three broad scenarios, purely for analytical purposes:

1) Constructive / bullish scenario. FDA and Pharming agree, after the Type A meeting, that the pediatric exposure question can be answered largely via additional PK analyses, population PK modelling and perhaps a small number of targeted patients, plus a robust analytical method clarification. In this scenario, the company could submit a reasonably compact resubmission package and potentially see a renewed review cycle within a 6–12-month window. The pediatric label might then come online with a delay, but without fundamentally changing the Joenja growth story.

2) Base / moderate delay scenario. The Agency concludes that a more structured additional PK study in low-weight children is required, with a few dozen patients and follow-up sufficient to characterize exposure and variability. Recruitment in ultra-rare pediatrics can be slow, so the approval could slip by 12–18 months relative to earlier expectations. Joenja 12+ continues to grow; the PIDs/CVID programs and KL1333 remain on track; the market simply discounts a later contribution from 4–11-year-old APDS patients.

3) Bearish / low-probability scenario. The additional data fail to fully resolve FDA’s concerns about exposure or analytical robustness, or the Agency raises new questions in subsequent cycles. In this tail scenario, pediatric approval could be materially delayed or even remain out of reach, and investors would increasingly demand that the valuation rely on the existing Joenja adult label and on the success of PIDs/CVID and KL1333. The CRL would then be a structural hit to the Joenja franchise rather than a timing issue.

At this stage, based on the wording of the CRL press release and the publicly available clinical data, the situation looks more like an exposure and CMC clean-up exercise than a fundamental efficacy problem. But until we see the outcome of the Type A meeting, it is prudent to treat timelines as fluid.

7. Key risks and things to monitor

In practical terms, the main risk points and monitoring items from here are:

• the timing and content of the Type A meeting with FDA and any subsequent update from Pharming on the required work-plan;
• the potential need for, and design of, any new pediatric PK study, particularly in the lowest weight bands;
• the continued performance of the 12+ Joenja franchise in APDS, including patient finding, reimbursement and geographic expansion;
• the evolution of the PIDs/CVID Phase II programs, which represent a much larger pool of patients if the data cooperate;
• progress in the FALCON pivotal trial of KL1333 and any further regulatory interactions on the mitochondrial disease asset;
• overall cash balance and burn, particularly as Abliva-related R&D and integration costs add to the baseline.

As always, it makes sense to cross-check any new development with Pharming’s investor relations page, the associated SEC filings (20-F, 6-K) and the full press-release archive, rather than relying on headlines alone.

8. Takeaway

The February 2026 CRL is a clear negative surprise for the pediatric APDS label expansion of Joenja, especially considering that the sNDA had been accepted with Priority Review. However, the nature of the issues – exposure in low-weight children and an analytical method for batch testing – suggests a technical and quantitative challenge rather than a complete rethinking of Joenja’s role in APDS.

For now, the core of the Pharming story remains: a growing Joenja franchise in 12+ APDS patients, a durable RUCONEST cash-flow engine, and a pipeline that targets PIDs with immune dysregulation, CVID and mitochondrial disease through KL1333. How quickly and cleanly the company can turn this CRL into an approvable pediatric file will determine whether the market views this as a temporary detour or as a more entrenched overhang on the Joenja growth curve.